INFLUENZA UPDATE

Infl uenza C exists but is rare
Infl uenza A and B account for almost all infl uenza-related outpatient visits and hospitalizations. Surveillance data from May 2013 through December 2016 showed that infl uenza C accounts for 0.5% of infl uenza-related outpatient visits and hospitalizations, particularly affecting children ages 6 to 24 months. Medical comorbidities and copathogens were seen in all patients requiring intensive care and in most hospitalizations. 5 Diagnostic tests for infl uenza C are not widely available.
Dogs and cats: Factories for new fl u strains?
While pigs and birds are the major reservoirs of infl uenza viral genetic diversity from which infection is transmitted to humans, dogs and cats have recently emerged as possible sources of novel reassortant infl uenza A. 6 With their frequent close contact with humans, our pets may prove to pose a signifi cant threat.
Obesity a risk factor for infl uenza
Obesity emerged as a risk factor for severe infl uenza in the 2009 pandemic. Recent data also showed that obesity increases the duration of infl uenza A virus shedding, thus increasing duration of contagiousness. Infl uenza a cardiovascular risk factor Previous data showed that infl uenza was a risk factor for cardiovascular events. Two recent epidemiologic studies from the United Kingdom showed that laboratory-confi rmed infl uenza was associated with higher rates of myocardial infarction and stroke for up to 4 weeks. 8, 9 Which strain is the biggest threat? Predicting which emerging infl uenza serotype may cause the next pandemic is diffi cult, but infl uenza A(H7N9), which had not infected humans until 2013 but has since infected about 1,600 people in China and killed 37% of them, appears to have the greatest potential. 10 National infl uenza surveillance programs and infl uenza-related social media applications have been developed and may get a boost from technology. A smartphone equipped with a temperature sensor can instantly detect one's temperature with great precision. A 2018 study suggested that a smartphone-driven thermometry application correlated well with national infl uenza-like illness activity and improved its forecast in real time and up to 3 weeks in advance.
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■ TRANSMISSION Humidity may not block transmission Animal studies have suggested that humidity in the air interferes with transmission of airborne infl uenza virus, partially from biologic inactivation. But when a recent study used humidity-controlled chambers to investigate the stability of the 2009 infl uenza A(H1N1) virus in suspended aerosols and stationary droplets, the virus remained infectious in aerosols across a wide range of relative humidities, challenging the common belief that humidity destabilizes respiratory viruses in aerosols.
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One sick passenger may not infect the whole plane Transmission of respiratory viruses on airplane fl ights has long been considered a potential avenue for spreading infl uenza. However, a recent study that monitored movements of individuals on 10 transcontinental US fl ights and simulated infl ight transmission based on these data showed a low probability of direct transmission, except for passengers seated in close proximity to an infectious passenger. The quadrivalent live-attenuated vaccine, which was not recommended during the 2016-2017 and 2017-2018 infl uenza seasons, has made a comeback and is recommended for the 2018-2019 season in people for whom it is appropriate based on age and comorbidities. 15 Although it was effective against infl uenza B and A(H3N2) viruses, it was less effective against the infl uenza A(H1N1)pdm09-like viruses during the 2013-2014 and 2015-2016 seasons.
A/Slovenia/2903/2015, the new A(H1N1) pdm09-like virus included in the 2018-2019 quadrivalent live-attenuated vaccine, is signifi cantly more immunogenic than its predecessor, A/Bolivia/559/2013, but its clinical effectiveness remains to be seen.
■ PROMOTING VACCINATION
How effective is it?
Infl uenza vaccine effectiveness in the 2017-2018 infl uenza season was 36% overall, 67% against A(H1N1), 42% against infl uenza B, and 25% against A(H3N2). 16 It is estimated that infl uenza vaccine prevents 300 to 4,000 deaths annually in the United States alone. 17 A 2018 Cochrane review 17 concluded that vaccination reduced the incidence of infl uenza by about half, with 2.3% of the population contracting the fl u without vaccination compared with 0.9% with vaccination (risk ratio 0.41, 95% confi dence interval 0.36-0.47). The same review found that 71 healthy adults need to be vaccinated to prevent 1 from experiencing infl uenza, and 29 to prevent 1 infl uenza-like illness.
Several recent studies showed that infl uenza vaccine effectiveness varied based on age and infl uenza serotype, with higher effectiveness in people ages 5 to 17 and ages 18 to 64 than in those age 65 and older. [18] [19] [20] A mathematical model of infl uenza transmission and vaccination in the United States determined that even relatively low-effi cacy infl uenza vaccines can be very useful if optimally distributed across age groups.
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Vaccination rates are low, and 'antivaxxers' are on the rise Although the infl uenza vaccine is recommended in the United States for all people age 6 months and older regardless of the state of their health, vaccination rates remain low. In 2016, only 37% of employed adults were vaccinated. The highest rate was for government employees (45%), followed by private employees (36%), followed by the self-employed (30%). 22 A national goal is to immunize 80% of all Americans and 90% of at-risk populations (which include children and the elderly). 23 The number of US hospitals that require their employees to be vaccinated increased from 37.1% in 2013 to 61.4% in 2017. 24 Regrettably, as of March 2018, 14 lawsuits addressing religious objections to hospital infl uenza vaccination mandates have been fi led. 25 Despite hundreds of studies demonstrating the effi cacy, safety, and cost savings of infl uenza vaccination, the antivaccine movement has been growing in the United States and worldwide. 26 All US states except West Virginia, Mississippi, and California allow nonmedical exemptions from vaccination based on religious or personal belief. 27 Several US metropolitan areas represent "hot spots" for these exemptions. 28 This may render such areas vulnerable to vaccine-preventable diseases, including infl uenza.
Herd immunity:
We're all in this together Some argue that the potential adverse effects and the cost of vaccination outweigh the benefi ts, but the protective benefi ts of herd immunity are signifi cant for those with comorbidities or compromised immunity.
Educating the public about herd immunity and local infl uenza vaccination uptake increases people's willingness to be vaccinated. 29 A key educational point is that at least 70% of a community needs to be vaccinated to Number needed to vaccinate to prevent 1 case of fl ulike illness in adults: 29 prevent community outbreaks; this protects everyone, including those who do not mount a protective antibody response to infl uenza vaccination and those who are not vaccinated.
■ DOES ANNUAL VACCINATION BLUNT ITS EFFECTIVENESS?
Some studies from the 1970s and 1980s raised concern over a possible negative effect of annual infl uenza vaccination on vaccine effectiveness. The "antigenic distance hypothesis" holds that vaccine effectiveness is infl uenced by antigenic similarity between the previous season's vaccine serotypes and the epidemic serotypes, as well as the antigenic similarity between the serotypes of the current and previous seasons. A meta-analysis of studies from 2010 through 2015 showed signifi cant inconsistencies in repeat vaccination effects within and between seasons and serotypes. It also showed that vaccine effectiveness may be infl uenced by more than 1 previous season, particularly for infl uenza A(H3N2), in which repeated vaccination can blunt the hemagglutinin antibody response. 30 A study from Japan showed that people who needed medical attention for infl uenza in the previous season were at lower risk of a similar event in the current season. 31 Prior-season infl uenza vaccination reduced current-season vaccine effectiveness only in those who did not have medically attended infl uenza in the prior season. This suggests that infection is more immunogenic than vaccination, but only against the serotype causing the infection and not the other serotypes included in the vaccine.
An Australian study showed that annual infl uenza vaccination did not decrease vaccine effectiveness against infl uenza-associated hospitalization. Rather, effectiveness increased by about 15% in those vaccinated in both current and previous seasons compared with those vaccinated in either season alone. 32 European investigators showed that repeated seasonal infl uenza vaccination in the elderly prevented the need for hospitalization due to infl uenza A(H3N2) and B, but not A(H1N1)pdm09. Recent studies confi rmed that high-dose vaccine is more effective than standard-dose vaccine in veterans 34 and US Medicare benefi ciaries. 35 The high-dose vaccine is rapidly becoming the primary vaccine given to people ages 65 and older in retail pharmacies, where vaccination begins earlier in the season than in providers' offi ces. 36 Some studies have shown that the standard-dose vaccine wanes in effectiveness toward the end of the infl uenza season (particularly if the season is long) if it is given very early. It remains to be seen whether the same applies to the high-dose infl uenza vaccine.
Some advocate twice-annual infl uenza vaccination, particularly for older adults living in tropical and subtropical areas, where infl uenza seasons are more prolonged. However, a recently published study observed reductions in infl uenza-specifi c hemagglutination inhibition and cell-mediated immunity after twiceannual vaccination. 37 
Vaccination is benefi cial during pregnancy
Many studies have shown the value of infl uenza vaccination during pregnancy for both mothers and their infants.
One recently published study showed that 18% of infants who developed infl uenza required hospitalization. 38 In that study, prenatal and postpartum maternal infl uenza vaccination decreased the odds of infl uenza in infants by 61% and 53%, respectively.
Another study showed that vaccine effectiveness did not vary by gestational age at vaccination. 39 Some studies have shown that infl uenza virus infection can increase susceptibility to certain bacterial infections. A post hoc analysis of an infl uenza vaccination study in pregnant women suggested that the vaccine was also associated with decreased rates of pertussis in these women.
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People were more willing to receive vaccine when told about herd immunity MOSSAD Factors that make vaccination less effective Several factors including age-related frailty and iatrogenic and disease-related immunosuppression can affect vaccine effectiveness.
Frailty. A recent study showed that vaccine effectiveness was 77.6% in nonfrail older adults but only 58.7% in frail older adults.
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Immunosuppression. Temporary discontinuation of methotrexate for 2 weeks after infl uenza vaccination in patients with rheumatoid arthritis improves vaccine immunogenicity without precipitating disease fl are. 42 Solid-organ and hematopoietic stem cell transplant recipients who received infl uenza vaccine were less likely to develop pneumonia and require intensive care unit admission. 43 The high-dose infl uenza vaccine is more immunogenic than the standard-dose vaccine in solid-organ transplant recipients.
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Statins are widely prescribed and have recently been associated with reduced infl uenza vaccine effectiveness against medically attended acute respiratory illness, but their benefi ts in preventing cardiovascular events outweigh this risk. 45 
■ FUTURE VACCINE CONSIDERATIONS
Moving away from eggs
During the annual egg-based production process, which takes several months, the infl uenza vaccine acquires antigenic changes that allow replication in eggs, particularly in the hemagglutinin protein, which mediates receptor binding. This process of egg adaptation may cause antigenic changes that decrease vaccine effectiveness against circulating viruses.
The cell-based baculovirus infl uenza vaccine grown in dog kidney cells has higher antigenic content and is not subject to the limitations of egg-based vaccine, although it still requires annual updates. A recombinant infl uenza vaccine reduces the probability of infl uenza-like illness by 30% compared with Hemagglutinin facilitates infection by binding to the host's cell-surface receptors, enabling fusion of the viral envelope with the host cell membrane.
Ribonucleoprotein (RNP) complex
consists of viral RNA associated with nucleoprotein (NP), nonstructural protein 1(NS1), and three polymerase proteins (PA, PB1, and PB2). Anti-infl uenza medications are effective, but underused the egg-based infl uenza vaccine, but also still requires annual updates. 46 The market share of these non-egg-based vaccines is small, and thus their effectiveness has yet to be demonstrated.
M2 (ion channel)
The US Department of Defense administered the cell-based infl uenza vaccine to about one-third of Armed Forces personnel, their families, and retirees in the 2017-2018 infl uenza seasons, and data on its effectiveness are expected in the near future.
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A universal vaccine would be ideal The quest continues for a universal infl uenza vaccine, one that remains protective for several years and does not require annual updates. 48 Such a vaccine would protect against seasonal epidemic infl uenza drift variants and pandemic strains. More people could likely be persuaded to be vaccinated once rather than every year.
The structure of the infl uenza virus can be depicted as a ball with spikes representing the hemagglutinin protein on its surface, each spike in the form of a stalk and a cap ( Figure  1) . 49, 50 All current infl uenza vaccines aim at the cap portion of the hemagglutinin protein.
Annual antigenic drift of infl uenza viruses alters the cap portion of the hemagglutinin protein, requiring annual vaccine updates. The stalk portion of the hemagglutinin protein is consistent among different infl uenza viruses and is not altered annually like the cap portion. Thus, a vaccine aimed at the stalk portion of the hemagglutinin protein has the potential to be a universal vaccine.
An ideal universal vaccine would be suitable for all age groups, at least 75% effective against symptomatic infl uenza virus infection, protective against all infl uenza A viruses (infl uenza A, not B, causes pandemics and seasonal epidemics), and durable through multiple infl uenza seasons. 51 Research and production of such a vaccine are expected to require funding of about $1 billion over the next 5 years.
Boosting effectiveness
Estimates of infl uenza vaccine effectiveness range from 40% to 60% in years when the vaccine viruses closely match the circulating viruses, and variably lower when they do not match. The effi cacy of most other vaccines given to prevent other infections is much higher.
New technologies to improve infl uenza vaccine effectiveness are needed, particularly for infl uenza A(H3N2) viruses, which are rapidly evolving and are highly susceptible to egg-adaptive mutations in the manufacturing process.
In one study, a nanoparticle vaccine formulated with a saponin-based adjuvant induced hemagglutination inhibition responses that were even greater than those induced by the high-dose vaccine. 52 Immunoglobulin A (IgA) may be a more effective vaccine target than traditional infl uenza vaccines that target IgG, since different parts of IgA may engage the infl uenza virus simultaneously. 54 This is because it is possible today to sequence a virus and insert the genetic material into a vaccine platform without ever having to grow the virus.
■ TREATMENT
Numerous studies have found anti-infl uenza medications to be effective. Nevertheless, in an analysis of the 2011-2016 infl uenza seasons, only 15% of high-risk patients were prescribed anti-infl uenza medications within 2 days of symptom onset, including 37% in those with laboratory-confi rmed infl uenza. 55 Fever was associated with an increased rate of antiviral treatment, but 25% of high-risk outpatients were afebrile. Empiric treatment of 4 high-risk outpatients with acute respiratory illness was needed to treat 1 patient with infl uenza. 55 Treatment with a neuraminidase inhibitor within 2 days of illness has recently been shown to improve survival and shorten duration of viral shedding in patients with avian infl uenza A(H7N9) infection. 56 Antiviral treatment within 2 days of illness is associated with improved outcomes in transplant recipients 57 and with a lower risk of otitis media in children.
MOSSAD
Appropriate anti-infl uenza treatment is as important as avoiding unnecessary antibiotics. Regrettably, as many as one-third of patients with laboratory-confi rmed infl uenza are prescribed antibiotics. 59 The US Food and Drug Administration warns against fraudulent unapproved overthe-counter infl uenza products.
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Baloxavir marboxil
Baloxavir marboxil is a new anti-infl uenza medication approved in Japan in February 2018 and anticipated to be available in the United States sometime in 2019.
This prodrug is hydrolyzed in vivo to the active metabolite, which selectively inhibits capdependent endonuclease enzyme, a key enzyme in initiation of messenger ribonucleic acid synthesis required for infl uenza viral replication. 61 In a double-blind phase 3 trial, the median time to alleviation of infl uenza symptoms is 26.5 hours shorter with baloxavir marboxil than with placebo. One tablet was as effective as 5 days of the neuraminidase inhibitor oseltamivir and was associated with greater reduction in viral load 1 day after initiation, and similar side effects. 62 Of concern is the emergence of nucleic acid substitutions conferring resistance to baloxavir; this occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 and 3 trials, respectively.
■ CLOSING THE GAPS
Several gaps in the management of infl uenza persist since the 1918 pandemic.
1 These include gaps in epidemiology, prevention, diagnosis, treatment, and prognosis.
• Global networks wider than current ones are needed to address this global disease and to prioritize coordination efforts.
• Establishing and strengthening clinical capacity is needed in limited resource settings. New technologies are needed to expedite vaccine development and to achieve progress toward a universal vaccine.
• Current diagnostic tests do not distinguish between seasonal and novel infl uenza A viruses of zoonotic origin, which are expected to cause the next pandemic. • Current antivirals have been shown to shorten duration of illness in outpatients with uncomplicated infl uenza, but the benefi t in hospitalized patients has been less well established.
• In 2007, resistance of seasonal infl uenza A(H1N1) to oseltamivir became widespread. In 2009, pandemic infl uenza A(H1N1), which is highly susceptible to oseltamivir, replaced the seasonal virus and remains the predominantly circulating A(H1N1) strain.
• A small-molecule fragment, N-cyclohexyaltaurine, binds to the conserved hemagglutinin receptor-binding site in a manner that mimics the binding mode of the natural receptor sialic acid. This can serve as a template to guide the development of novel broad-spectrum small-molecule anti-infl uenza drugs. 63 • Biomarkers that can accurately predict development of severe disease in patients with infl uenza are needed. 
